Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Estrella Immunopharma ( (ESLA) ) has shared an announcement.
On May 30, 2025, Estrella Immunopharma entered into a securities purchase agreement for a private placement, raising approximately $3.35 million by issuing 2,233,334 shares at $1.50 each. The proceeds will support the completion of Phase I of the STARLIGHT-1 clinical trial for EB103, a CD19-Redirected ARTEMIS® T-cell therapy for B-cell non-Hodgkin’s lymphoma. This financing reflects investor confidence in Estrella’s innovative therapies and strengthens its financial position to advance clinical development.
The most recent analyst rating on (ESLA) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Estrella Immunopharma stock, see the ESLA Stock Forecast page.
More about Estrella Immunopharma
Estrella Immunopharma is a clinical-stage biopharmaceutical company focused on developing CD19 and CD22-targeted ARTEMIS® T-cell therapies for treating cancers and autoimmune diseases. The company’s lead product candidate, EB103, utilizes ARTEMIS® technology to target CD19, a protein found on most B-cell leukemias and lymphomas.
Average Trading Volume: 51,473
Technical Sentiment Signal: Sell
Current Market Cap: $35.08M
See more data about ESLA stock on TipRanks’ Stock Analysis page.